



PATENT
Customer No. 22,852
Attorney Docket No. 08201.0027-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
BROWNING et al.)	Group Art Unit: 1633
Application No.: 10/077,137)	Examiner: Not yet assigned
Filed: February 15, 2002)	
For: BAFF RECEPTOR (BCMA), AN)	Confirmation No.: 2907
IMMUNOREGULATORY AGENT)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents including any copending patent applications, are attached, with the exception of the voluminous sequence listing portions of WO 02/02641 and WO 03/055979. Should the Examiner require the complete documents, Applicants will provide them upon request.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: *July 12, 2004*

By: 
Leslie A. McDonell
Reg. No. 34,872



SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08201.0027-00000	Appln. No.	10/077,137
Applicant	BROWNING et al.		
Filing Date	February 15, 2002	Group:	1633

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,969,102	10/19/1999	Bram et al.	530	350	
	6,297,367	10/02/2001	Tribouley	536	23.5	
	6,316,222	11/13/2001	Bram et al.	435	69.1	
	6,475,986	11/05/2002	Aggarwal	514	12	
	6,541,224	04/01/2003	Yu et al.	435	69.5	

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
WO 00/26244	05/11/2000	PCT	CO7K	14/00	
WO 00/39295	07/06/2000	PCT	C12N	15/12	
WO 00/40716	07/13/2000	PCT	C12N	15/11	
WO 00/50633	08/31/2000	PCT	C12Q	1/00	
WO 00/58362	10/05/2000	PCT	CO7K	16/00	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Hahne et al., "APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth," <i>J. Exp. Med.</i> 188:1185-1190 (1998)
Kashii, Y. et al., "CONSTITUTIVE EXPRESSION AND ROLE OF THE TNF FAMILY LIGANDS IN APOPTOTIC KILLING OF TUMOR CELLS BY HUMAN NK CELLS," <i>J. Immunol.</i> 163:5358-66 (1999)
Ward, P. and Mulligan, M. "BLOCKING OF ADHESION MOLECULES IN VIVO AS ANTI-INFLAMMATORY THERAPY," <i>Ther. Immunol.</i> 1:165-71 (1994)
Ware, C., "APRIL AND BAFF CONNECT AUTOIMMUNITY AND CANCER," <i>J. Exp. Med.</i> 192:F35-F37 (2000)

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08201.0027-00000	Appln. No.	10/077,137
Applicant	BROWNING et al.		
Filing Date	February 15, 2002	Group:	1633

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	WO 01/24811	04/12/2001	PCT	A61K	38/17	
	WO 02/02641	01/10/2002	PCT	C07K	16/00	
	WO 02/18620	03/07/2002	PCT	C12Q		
	WO 03/055979	07/10/2003	PCT	C12Q		
	WO 97/33902	09/18/1997	PCT	C07H	21/02	
	WO 98/18921	05/07/1998	PCT	C12N	15/12	
	WO 98/27114	06/25/1998	PCT	C07K	14/00	
	WO 98/55620	12/10/1998	PCT	C12N	15/19	
	WO 98/55621	12/10/1998	PCT	C12N	15/19	
	WO 99/11791	03/11/1999	PCT	C12N	12/12	
	WO 99/33980	07/08/1999	PCT	C12N	15/12	
	EP 0 869 180 A1	10/07/1998	EPC	C12N	15/19	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	von Bulow & Bram, "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily," <i>Science</i> 278:138-141 (1997)
	Xia et al., "TACI is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation," <i>J. Exp. Med.</i> 192:137-143 (2000)
	Yu et al., "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity," <i>Nature Immunol.</i> 1:252-256 (2000)
	Published U.S. Patent Application No. 10/214,065, filed August 7, 2002; Publication No. US 2003-0023038-A1, published January 30, 2003

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



OMB No. 0651-0011

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08201.0027-00000	Appln. No.	10/077,137
Applicant	BROWNING et al.		
Filing Date	February 15, 2002	Group:	1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Published U.S. Patent Application No. 10/380,703, filed March 17, 2003, Publication No. US-2004-0072188-A1, published April 15, 2004.
	Published U.S. Patent Application No. 09/911,777, filed July 21, 2001; Publication No. US-2002-0037852-A1, published March 28, 2002
	Published U.S. Patent Application No. 10/115,192, filed April 2, 2002; Publication No. US-2003-0082175-A1, published May 1, 2003
	Published U.S. Patent Application No. 10/077,438, filed February 15, 2002; Publication No. US-2002-0165156-A1, published November 7, 2002
	Published U.S. Patent Application No. 10/258,368, filed June 23, 2003; Publication No. US-2004-0013674-A1, published January 22, 2004

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce